See the latest Beam Therapeutics Inc stock price (BEAM:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward ...